| 產品名稱 |
NCI-H920 [H920] |
| 商品貨號 |
B165377 |
| Organism |
Homo sapiens, human |
| Tissue |
lung |
| Product Format |
frozen |
| Culture Properties |
suspension; floating aggregates |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease |
stage 4,adenocarcinoma; non-small cell lung cancer |
| Age |
43 years |
| Gender |
male |
| Ethnicity |
Caucasian |
| Applications |
The line was established in December 1984. |
| Derivation |
The line was established in December 1984. |
| Clinical Data |
The patient received prior radiation therapy. The patient was a smoker. male Caucasian 43 years |
| Comments |
The line was established in December 1984. The patient received prior radiation therapy. The patient was a smoker. 75 pack years. |
| Complete Growth Medium |
The base medium for this cell line is RPMI-1640 Medium (ATCC 30-2001).To make the complete growth medium, add the following components to the base medium: Fetal Bovine Serum (FBS; ATCC 30-2020) to a final concentration of 5%. |
| Subculturing |
These cells grow as floating aggregates of round cell clusters that should not be broken up. The culture can be maintained by simply adding fresh medium as the cell density increases. This cell line cannot be accurately counted, and single cells are not viable. |
| Cryopreservation |
Culture medium, 95%; DMSO, 5% |
| STR Profile |
Amelogenin: X CSF1PO: 12 D13S317: 11 D16S539: 11,13 D5S818: 13 D7S820: 10,11 THO1: 9.3 TPOX: 8,11 vWA: 19 |
| Name of Depositor |
AF Gazdar, JD Minna |
| Deposited As |
Homo sapiens |
| Year of Origin |
1984 |
| References |
NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.
|
